Assenagon Asset Management S.A. trimmed its position in shares of Oscar Health, Inc. (NYSE:OSCR – Free Report) by 30.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 732,285 shares of the company’s stock after selling 327,244 shares during the period. Assenagon Asset Management S.A. owned about 0.32% of Oscar Health worth $6,700,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in OSCR. Southeastern Asset Management Inc. TN grew its holdings in Oscar Health by 30.8% during the 4th quarter. Southeastern Asset Management Inc. TN now owns 14,576,904 shares of the company’s stock valued at $35,859,000 after purchasing an additional 3,430,032 shares during the last quarter. Capital World Investors bought a new position in Oscar Health in the 1st quarter worth about $27,427,000. Vanguard Group Inc. grew its stake in Oscar Health by 18.6% in the 3rd quarter. Vanguard Group Inc. now owns 14,127,934 shares of the company’s stock worth $78,693,000 after acquiring an additional 2,211,743 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in Oscar Health in the 1st quarter worth about $13,349,000. Finally, State Street Corp grew its stake in Oscar Health by 512.6% in the 2nd quarter. State Street Corp now owns 2,069,734 shares of the company’s stock worth $8,796,000 after acquiring an additional 1,731,860 shares in the last quarter. 75.70% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
OSCR has been the topic of a number of research analyst reports. Raymond James initiated coverage on shares of Oscar Health in a research note on Friday, March 22nd. They issued an “outperform” rating and a $20.00 target price on the stock. Wells Fargo & Company upped their price target on shares of Oscar Health from $12.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. The Goldman Sachs Group upped their price target on shares of Oscar Health from $8.00 to $16.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. Finally, TheStreet raised shares of Oscar Health from a “d” rating to a “c-” rating in a research report on Wednesday, February 21st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $13.50.
Read Our Latest Research Report on Oscar Health
Oscar Health Stock Up 4.6 %
OSCR stock traded up $0.66 during midday trading on Friday, hitting $14.87. 4,073,649 shares of the stock traded hands, compared to its average volume of 2,902,570. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.37. The stock’s fifty day simple moving average is $14.75 and its 200-day simple moving average is $9.91. Oscar Health, Inc. has a 1-year low of $4.72 and a 1-year high of $18.55.
Oscar Health (NYSE:OSCR – Get Free Report) last released its quarterly earnings results on Wednesday, February 7th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.08. The company had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.43 billion. Oscar Health had a negative net margin of 4.62% and a negative return on equity of 29.99%. The firm’s revenue was up 43.9% on a year-over-year basis. During the same quarter last year, the business earned ($1.05) earnings per share. As a group, analysts anticipate that Oscar Health, Inc. will post -0.23 earnings per share for the current fiscal year.
Oscar Health Profile
Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.
See Also
Before you consider Oscar Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Oscar Health wasn’t on the list.
While Oscar Health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.